# Alirocumab and Plaque Burden In Familial Hypercholesterolaemia

Study · id `cardio:ct-nct05465278` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05465278](<https://clinicaltrials.gov/study/NCT05465278>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05465278

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

## Technical summary

Registry record NCT05465278. Allocation not applicable; no masking; primary purpose treatment. Start 2018-05-01 (actual); primary completion 2022-03-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 104 participants (enrolled count; ClinicalTrials.gov record NCT05465278, source copy `cardio:ctgov-nct05465278-2022-07-19`, retrieved 2026-10-31)
- Started: 2018-05-01 (actual) (ClinicalTrials.gov record NCT05465278, source copy `cardio:ctgov-nct05465278-2022-07-19`, retrieved 2026-10-31)
- Primary completion: 2022-03-30 (actual) (ClinicalTrials.gov record NCT05465278, source copy `cardio:ctgov-nct05465278-2022-07-19`, retrieved 2026-10-31)
- Completion: 2022-03-30 (actual) (ClinicalTrials.gov record NCT05465278, source copy `cardio:ctgov-nct05465278-2022-07-19`, retrieved 2026-10-31)
- Countries: Spain (ClinicalTrials.gov record NCT05465278, source copy `cardio:ctgov-nct05465278-2022-07-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05465278-2022-07-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Alirocumab and Plaque Burden In Familial Hypercholesterolaemia
- Acronym: ARCHITECT
- Condition: Familial Hypercholesterolemia
- Intervention (Drug): Alirocumab
- Lead sponsor: Fundación Hipercolesterolemia Familiar
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)

## Provenance

Content hash: 8dda07eb72e1bce68ec281b9568d381f07e311636749606f27db68d55bf28b62
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
